Compare HBAN & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBAN | INSM |
|---|---|---|
| Founded | 1866 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4B | 30.1B |
| IPO Year | N/A | 2000 |
| Metric | HBAN | INSM |
|---|---|---|
| Price | $16.72 | $146.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 24 |
| Target Price | $19.40 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 21.9M | 2.3M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.22 | $177.03 |
| Revenue Next Year | $8.97 | $66.55 |
| P/E Ratio | $12.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.36 | $63.81 |
| 52 Week High | $19.44 | $212.75 |
| Indicator | HBAN | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 60.79 | 43.43 |
| Support Level | $15.05 | $136.24 |
| Resistance Level | $17.90 | $149.08 |
| Average True Range (ATR) | 0.33 | 6.05 |
| MACD | 0.19 | -0.71 |
| Stochastic Oscillator | 94.39 | 16.32 |
Huntington is a regional US bank with over $200 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.